Life sciences companies turn to WilmerHale to resolve their most complex intellectual property disputes, including bet-the-company patent and licensing disputes, Hatch-Waxman litigation and litigation under the BPCIA. From conducting early assessments of clients' patent and product portfolios to representing clients in all phases of litigation, we understand the unique tactics and strategies implicated by life sciences litigation, and work with clients to implement an overarching strategy designed to protect their most valuable assets.
Among other things, WilmerHale has represented companies in high stakes disputes with competitors and also has a well-established track record of successfully representing companies in Hatch-Waxman litigation and litigation under the BPCIA. We have extensive experience at all stages of litigation, including preparation in advance of any litigation, handling disputes involving multiple patents and numerous defendants, litigating patent infringement matters through trial in the district courts and appeals at the Federal Circuit, and achieving resolution of appropriate matters through settlement. In the last five years, we have handled more than 145 Hatch-Waxman matters and are also representing clients in matters arising under the BPCIA.
WilmerHale has served as national trial and appellate counsel in multi-jurisdictional patent infringement actions and has successfully represented life sciences clients before the International Trade Commission, district courts throughout the United States, the Federal Circuit and the US Supreme Court. Our lawyers also have a substantial track record representing patent owners and petitioners in Inter Partes Review proceedings before the Patent Trial and Appeal Board, and coordinating IPR proceedings with pending litigation. By combining our intellectual property expertise with our trial and appellate strengths we are able to shape a litigation strategy that maximizes the likelihood of success for our clients.